However, the anti-TSLP human monoclonal antibody tezepelumab is modest or nonsignificant compared to placebo in improving pruritic skin lesion in AD, as shown in a randomized phase 2a clinical trial [177,178]. The gene discussed is TSLP; the disease is Alzheimer disease.